芪仙汤联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘慢性持续期痰哮证疗效及对气道慢性炎症的影响  

Efficacy of Qixian Decoction(芪仙汤)Combined with Budesonide and Formoterol Powder for Inhalation on Bronchial Asthma with Phlegm Wheezing Syndrome in Chronic Persistent Stage and Their Effects on Chronic Airway Inflammation in Patients

作　　者：史兆雯 罗旭明[1] 王雄彪[1] 肖震炜 SHI Zhaowen;LUO Xuming;WANG Xiongbiao;XIAO Zhenwei(Putuo Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200062,China;School of Rehabilitation Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属普陀医院,上海200062 [2]上海中医药大学康复医学院,上海201203

出　　处：《中华中医药学刊》2023年第7期80-83,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家中医药管理局中医传承基地建设项目(2018CCJD0078-1);上海市普陀区卫生健康系统临床特色专科建设计划项目(2020tszk02);上海中医药大学附属普陀医院院级科研项目(2019323)。

摘　　要：目的 探讨芪仙汤联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘(Bronchial asthma, BA)慢性持续期痰哮证疗效及对患者气道慢性炎症的影响。方法 选取2020年6月—2021年12月BA慢性持续期痰哮证患者140例,随机数字表法分为两组,每组70例。对照组予以布地奈德福莫特罗粉吸入剂治疗,观察组予以芪仙汤联合布地奈德福莫特罗粉吸入剂治疗。比较两组临床疗效、不良反应发生率、哮喘控制率及治疗前后哮喘控制测试(Asthma control test, ACT)评分、肺通气指标[第1秒呼气容积(Forced expiratory volume in one second, FEV1)、最大呼气流量(Peak expiratory flow, PEF)、呼吸流速峰值(Peak expiratory flow rate, PEFR)]、血清炎性因子[白细胞介素4(Interleukin 4,IL-4)、白细胞介素10(Interleukin 10,IL-10)、白细胞介素13(Interleukin 13,IL-13)]、气道重塑指标[血管内皮生长因子(Vascular endothelial growth factor, VEGF)、碱性成纤维细胞生长因子(Basic fibroblast growth factor, b-FGF)、血小板衍生生长因子(Platelet derived growth factor, PDGF-BB)]、布地奈德福莫特罗粉吸入剂用量、不良反应。结果 (1)临床疗效:观察组总有效率(92.86%,65/70)优于对照组(80.00%,56/70)(P<0.05);(2)哮喘控制情况:治疗后,观察组ACT评分及哮喘控制率高于对照组(P<0.05);(3)肺通气指标:观察组治疗后FEV1、PEF高于对照组,PEFR低于对照组(P<0.05);(4)血清炎性因子:观察组治疗后血清IL-4、IL-13水平低于对照组,IL-10水平高于对照组(P<0.05);(5)气道重塑指标:观察组治疗后血清VEGF、b-FGF、PDGF-BB水平低于对照组(P<0.05);(6)观察组布地奈德福莫特罗粉吸入剂每日平均用量(419.87±71.25)μg,显著低于对照组的(493.64±64.72)μg(P<0.05)。(7)不良反应:两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论 芪仙汤联合布地奈德福莫特罗粉吸入剂治疗BA慢性持续期痰哮证,疗效确切,能有效提高哮喘控制效果,�Objective To investigate the efficacy of Qixian Decoction(芪仙汤)combined with Budesonide and Formoterol Powder for Inhalation in the treatment of chronic persistent bronchial asthma(BA)with phlegm wheezing syndrome and their effects on chronic airway inflammation in patients.Methods From June 2020 to December 2021,140 patients with chronic persistent BA with phlegm wheezing syndrome in the hospital were selected and grouped by random number table,70 cases in each.The control group was treated with Budesonide and Formoterol Powder for Inhalation,and the observation group was treated with Qixian Decoction combined with Budesonide and Formoterol Powder for Inhalation.The clinical efficacy,incidence of adverse reactions,asthma control rate,asthma control test(ACT)score,lung ventilation indicators[forced expiratory volume in one second(FEV 1),peak expiratory flow(PEF),peak expiratory flow rate(PEFR)],serum inflammatory factors[interleukin 4(IL-4),interleukin 10(IL-10),interleukin 13(IL-13)],airway remodeling indicators[vascular endothelial growth factor(VEGF),basic fibroblast growth factor(b-FGF),platelet derived growth factor(PDGF-BB)]before and after treatment,dosage of Budesonide and Formoterol Powder for Inhalation and adverse reactions were compared between the two groups.Results(1)Clinical efficacy:The total effective rate in the observation group was better than that in the control group[92.86%(65/70)VS 80.00%(56/70)],P<0.05).(2)Asthma control:After treatment,the ACT score and asthma control rate in the observation group were higher than those in the control group(P<0.05).(3)Lung ventilation index:FEV 1 and PEF were higher in the observation group and PEFR was lower than those in the control group after treatment(P<0.05).(4)Serum inflammatory factors:After treatment,serum levels of IL-4 and IL-13 in the observation group were lower than those in the control group,and IL-10 level was higher than that in the control group(P<0.05).(5)Airway remodeling indicators:Serum levels of VEGF,b-FGF and PDGF-BB in the ob

关 键 词：芪仙汤 支气管哮喘 慢性持续期 痰哮证 气道慢性炎症 

分 类 号：R256.12[医药卫生—中医内科学]